235 East 42nd Street
About Pfizer Inc.
Imagine touching the lives of people everywhere. Imagine reaching beyond the ordinary and impacting something greater than the bottom line. Imagine influencing some of the most critical issues facing healthcare today.
At Pfizer Global Research & Development (PGRD), Pfizer’s visionary discovery and development division and the largest research-based biomedical and pharmaceutical company in the world, we're not content waiting to witness the evolution of our industry. Instead, we’re driven by science, building on our current successes and capabilities, playing a critical role in developing the most compelling story of scientific discoveries.
To date, PGRD has brought to market a wide range of medicines, such as Lipitor® (atorvastatin calcium), Zithromax® (azithromycin), Viracept® (nelfinavir mesylate), Zoloft® (sertraline hydrochloride), Viagra® (sildenafil citrate), and our newest smoking cessation medicine, Chantix® (varenicline). And, today, with a broad research pipeline that spans many therapeutic areas, we are determined to bring even more cures to the marketplace.
But there is much more work to be done and we can’t do it alone. We’re always seeking those who share our belief that science can improve our world, that by working together we can bring exciting new therapies to patients on a global scale and forever change the way we improve the health and well-being of all people.
Why Join Pfizer?
Pfizer offers the opportunity to work on promising research, access to unparalleled resources and world-class facilities, and the chance to work with some of the brightest and most driven individuals in the pharmaceutical industry.
At Pfizer, we build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues. As an integral member of our team, you'll find myriad opportunities to assert your professional independence as you generate results that will advance our ultimate goal of creating life-enhancing therapies.
In addition to creating the environment for innovation, our values have led to numerous corporate awards acknowledging excellence in many domains - with investors, our business partners, and our employees. We've been praised as “One of the 100 Best Companies for Working Mothers” by Working Mother® Magazine (9/07), honored with “The Best Employers for Healthy Lifestyles 2007 Award” by the National Business Group on Health (5/07), and awarded by the Women's Business Enterprise National Council on its annual listing of America's Top Corporations for Women's Business Enterprises (3/07).
At PGRD, your success is critical to our success. PGRD offers world-class career opportunities, directing resources and time that result in a high-level scientific professional track. Our employees and external rankings with the leading authorities attest to the fact that PGRD is one of the best companies to work for - where you choose a lifestyle - not just a job.
• La Jolla, CA
Located north of downtown San Diego, La Jolla boasts southern California's most beautiful and majestic coastline, with an abundance of cultural, outdoor recreation, and big city activities. Home to Salk Institute and Scripps Research Institute - two renowned academic institutions - and many major biotechnology and telecommunications firms, La Jolla offers a rich environment for both scientists and engineers.
• New London and Groton, CT
Located on the southeastern Connecticut seashore in a historical New England vacation area known for its seafood, easy pace of living, and nautically related recreational activities. It's also within reasonable driving distance to a wealth of greater academic institutions, and within a couple of hours of Boston and New York.
• St. Louis, MO
Known as the Gateway to the West, St. Louis is a diverse, vibrant metropolitan area of 2.5 million, with a broad-based economy. Residents enjoy professional sports teams, a world-class symphony orchestra, botanical gardens, and numerous other outdoor activities. Additionally, scientists have the opportunity to collaborate with researchers at Washington University School of Medicine.
• Sandwich, UK
Sandwich, once a major port in England but now 2 miles from the sea, is one of the best-preserved Medieval towns in the UK, with its old town walls and "Kent Peg" roof houses. Situated close to the city of Canterbury and only 80 miles from London, the area is steeped in history and is ideal for those who enjoy water sports. The rail links across the English Channel also mean that you can be in France within an hour, providing access to the whole of Europe.
At PGRD, we celebrate the talents and diversity of our employees. We respect our employees' lives and provide a multitude of resources and supports to help foster a work/life balance. Also, in addition to our outstanding career opportunities and quality of life, we offer a wide array of topnotch and leading-edge benefits, competitive compensation, and exceptional long-term financial rewards designed to ensure your well-being and financial security. We offer you choices so you can craft a plan that meets your individual and family needs.
Your talent can change the world. Join us.
To learn more about our people, our products, and our plans for the future, visit www.pfizer.jobs
We’re proud to be an equal opportunity employer and welcome applications from people with different experiences, backgrounds, and ethnic origins.
Founder: Charles Pfizer
CEO: Ian C. Read
CMO: Freda C. Lewis-Hall, M.D., DFAPA
CFO: Frank D’Amelio
Please click here for clinical trial information.
For more information, visit
www.pfizer.com and follow us on www.twitter.com/Pfizer.
Tweets by Pfizer
Innovating for Healthier Lives
3643 articles with Pfizer Inc.
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
Genentech, released follow-up data from its Phase III ALEX trial comparing its Alecensa (alectinib) to Pfizer’s Xalkori (crizotinib) in late-stage non-small cell lung cancer (NSCLC).
The U.S. Food and Drug Administration (FDA) approved Pfizer’s Retacrit (epoetin alfa-epbx), a biosimilar to Amgen’s Epogen/Procrit (epoetin alfa). The drugs treat anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in HIV patients.
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) for the treatment of anemia
Vyriad, based in Rochester, Minnesota, announced it is building out its facility in 25,000 square feet of space it is leasing on the IBM Campus in Rochester.
Jazz Sets Aside $57M to Settle Probe into Charitable Giving as DOJ Continues to Investigate Poten...
5/11/2018Jazz Pharmaceuticals set aside $57 million in the first quarter of 2018 to settle an investigation by the U.S. Attorney's Office for the District of Massachusetts regarding its support of 501(c)(3) organizations that provide financial assistance to Medicare patients.
As Boston-based Rhythm Pharmaceuticals moves its lead obesity treatment into a second Phase III trial, the company was bolstered by the publication of longer-term data from its Phase II study of setmelanotide in Nature Medicine.
The uses of viruses as therapeutics is growing, largely because new gene therapy treatments require viruses.
Alnylam Pharmceuticals reported preclinical results that supports advancement of its RNA interference (RNAi) therapeutics for central nervous system disorders into the clinic.
The U.S. Food and Drug Administration (FDA) granted Genentech’s Tecentriq triple combination with Avastain (bevacizumab), paclitaxel and carboplatin (chemotherapy) Priority Review for first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
As we get closer to seeing the U.S. Food and Drug Administration green light the first gene therapy for hemophilia, analysts estimate that the cost of the probable one-time treatment could have a whopping price-tag of $1.5 million.
The Wilmington, Massachusetts-based contract research organization (CRO) Charles River Laboratories International extended its current collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
Sam Isaly has finally stepped down from his position as a managing member OrbiMed more than four months after he was accused of sexual harassment. Sexual harassment allegations have been in the forefront of the news cycles for months as the #MeToo movement gained traction.
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
5/3/2018Regeneron has halted high dose treatment of a Phase III osteoarthritis drug following a risk-benefit assessment conducted by an Independent Data Monitoring Committee.
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Sandoz, a division of Novartis, for its Biologics Licensing Application (BLA) for its biosimilar to Roche/Genentech’s Rituxan.
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.
Iterum Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) to initiate an initial public offering (IPO). The company hopes to raise $92 million.